Garland J. Scott
SEC-identified person · CIK 1533228 Identifier-verified
Public-company roles (from insider filings)
| Company | Capacity as filed | Filings |
|---|---|---|
| Olema Pharmaceuticals, Inc. OLMA | Director | filed 2023 - 2026 |
| LB Pharmaceuticals INC LBRX | Director | filed 2025 - 2026 |
| Day One Biopharmaceuticals, Inc. DAWN | Director | filed 2021 - 2026 |
| Imara Inc. IMRA | Director | filed 2026 - 2026 |
| ALX Oncology Holdings INC ALXO | Director | filed 2022 - 2026 |
| Calithera Biosciences, Inc. CALA | Director | filed 2020 - 2022 |
| Portola Pharmaceuticals INC PTLA | Director · President and CEO | filed 2018 - 2020 |
| Karyopharm Therapeutics Inc. KPTI | Director | filed 2014 - 2019 |
| Relypsa Inc RLYP | SVP & Chief Commercial Officer | filed 2014 - 2016 |
| Exelixis, INC. XEL | EVP & Chief Commerical Officer | filed 2011 - 2013 |
All roles under one Commission-assigned identifier - the same person by the SEC's own record, not by name matching. From the SEC's insider-transaction filings (Forms 3, 4 and 5). Every reporting director and officer carries a Commission-assigned identifier (CIK), so these footprints are identifier-verified - no name matching involved. Insiders file when they transact, so dates are filing dates: "last filed" never means "served until". This layer is not yet joined to the nonprofit register - identity joins ship only after independent review.